Comparative Pharmacology
Head-to-head clinical analysis: DYCILL versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCILL versus LAROTID.
DYCILL vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic